| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology and the Brain Research Institute, University of Chicago, IL.
Supported by NINDS-PO1 NS 24575 (B.G.W.A.), gifts from the Butz and the Brain Research Foundations (B.G.W.A.), and a grant from Berlex, Inc (B.G.W.A.).
Received January 26, 1995. Accepted in final form April 2, 1995.
Address correspondence and reprint requests to Dr. Barry G.W. Arnason, University of Chicago, Department of Neurology, 5841 S. Maryland Avenue--MC 2030, Chicago, IL 60637.
Fifteen percent of multiple sclerosis patients about to be treated with interferon beta-1b exhibited elevated numbers of circulating interferon-gamma-secreting cells, defined as a value that exceeded the mean value for healthy controls by more than two standard deviations. Sixty percent of patients receiving the drug exhibited elevated interferon-gamma-secreting cell numbers during their first 2 months of treatment. Values normalized after 3 months. Prednisone treatment during the first month on the drug prevented the interferon-gamma-secreting cell surge.
NEUROLOGY 1995;45: 2173-2177
This article has been cited by other articles:
|
|
 |
|
  M Krakauer, P Sorensen, M Khademi, T Olsson, and F Sellebjerg Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression Multiple Sclerosis, June 1, 2008; 14(5): 622 - 630. [Abstract] [PDF]
|
|
|
|
|
|
K. Hamamcioglu and A. Reder Interferon-{beta} regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis Multiple Sclerosis, May 1, 2007; 13(4): 459 - 470. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Waubant, S. Vukusic, L. Gignoux, F. D. Dubief, I. Achiti, S. Blanc, C. Renoux, and C. Confavreux Clinical characteristics of responders to interferon therapy for relapsing MS Neurology, July 22, 2003; 61(2): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Franciotta, E Zardini, R Bergamaschi, L Andreoni, and V Cosi Interferon {gamma} and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment J. Neurol. Neurosurg. Psychiatry, January 1, 2003; 74(1): 123 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Dhib-Jalbut, M Chen, K Henschel, D Ford, K Costello, and H Panitch Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 485 - 491. [Abstract] [PDF]
|
|
|
|
|
|
V. W. Yong Differential mechanisms of action of interferon-{beta} and glatiramer acetate in MS Neurology, September 24, 2002; 59(6): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Soos, O. Stuve, S. Youssef, M. Bravo, H. M. Johnson, H. L. Weiner, and S. S. Zamvil Cutting Edge: Oral Type I IFN-{tau} Promotes a Th2 Bias and Enhances Suppression of Autoimmune Encephalomyelitis by Oral Glatiramer Acetate J. Immunol., September 1, 2002; 169(5): 2231 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Durelli, B. Ferrero, A. Oggero, E. Verdun, A. Ghezzi, E. Montanari, and M. Zaffaroni Liver and thyroid function and autoimmunity during interferon-{beta}1b treatment for MS Neurology, October 23, 2001; 57(8): 1363 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Von Raison, H. Abboud, C. S. Val, P. Brugieres, and P. Cesaro Acute demyelinating disease after interferon {beta}-1a treatment for multiple sclerosis Neurology, November 14, 2000; 55(9): 1416 - 1417. [Full Text] [PDF]
|
|
|
|
|
|
H F Petereit, N Richter, R Pukrop, and S Bamborschke Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients Multiple Sclerosis, February 1, 2000; 6(1): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
E. U. Walther and R. Hohlfeld Multiple sclerosis: Side effects of interferon beta therapy and their management Neurology, November 1, 1999; 53(8): 1622 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gayo, L. Mozo, A. Suarez, A. Tunon, C. Lahoz, and C. Gutierrez Interferon beta-1b treatment modulates TNF{alpha} and IFN{gamma} spontaneous gene expression in MS Neurology, June 1, 1999; 52(9): 1764 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bongioanni, S. Mosti, G. Moscato, F. Lombardo, C. Manildo, and G. Meucci Decreases in T-Cell Tumor Necrosis Factor {alpha} Binding With Interferon Beta Treatment in Patients With Multiple Sclerosis Arch Neurol, January 1, 1999; 56(1): 71 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Ferrarini, S Sivieri, M Buttarello, A Facchinetti, P Perini, and P Gallo Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-{beta}1b-treated multiple sclerosis patients Multiple Sclerosis, June 1, 1998; 4(3): 174 - 177. [Abstract] [PDF]
|
|
|
|
|
|
M. Schluep, G. van Melle, H. Henry, C. Stadler, B. Roth-Wicky, and P. J Magistretti In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis Multiple Sclerosis, June 1, 1998; 4(3): 198 - 202. [Abstract] [PDF]
|
|
|
|
|
|
B. W. van Oosten, F. Barkhof, P. E. T. Scholten, B. M. E. von Blomberg, H. J. Ader, and C. H. Polman Increased Production of Tumor Necrosis Factor {alpha}, and Not of Interferon {gamma}, Preceding Disease Activity in Patients With Multiple Sclerosis Arch Neurol, June 1, 1998; 55(6): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. X. Qu, A. Dayal, M. A. Jensen, and B. G. W. Arnason All-trans Retinoic Acid Potentiates the Ability of Interferon Beta-1b to Augment Suppressor Cell Function in Multiple Sclerosis Arch Neurol, March 1, 1998; 55(3): 315 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Sarchielli, O Presciutti, R Tarducci, G Gobbi, A Alberti, G P Pelliccioli, A Orlacchio, and V Gallai 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta -1a: results of a preliminary study J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dhib-Jalbut Mechanisms of interferon beta action in multiple sclerosis Multiple Sclerosis, December 1, 1997; 3(6): 397 - 401. [PDF]
|
|
|
|
|
|
H. Petereit, S. Bamborschke, A. Esse, and W. Heiss Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis Multiple Sclerosis, June 1, 1997; 3(3): 180 - 183. [Abstract] [PDF]
|
|
|
|
|
|
P. Byskosh and A. Reder Interferon {beta}-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis Multiple Sclerosis, April 1, 1996; 1(5): 262 - 269. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
